Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101930 · ClinicalTrials.gov registry record · Phase 4
Cardiovascular Effects of GLP-1 Receptor Activation
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 329
- Enrollment target
NCT03101930: Completed Phase 4 study, sponsored by Vanderbilt University Medical Center.
NCT03101930 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 329 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03101930, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 329 participants
- Enrollment target
Study Summary
This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk.
Primary Outcome
Brachial artery diameter is measured under basal conditions and during reactive hyperemia (Flow Mediated Dilation as %)
Interventions
- DRUG Sitagliptin
- DRUG Placebos
- DRUG Liraglutide
- DRUG Exendin (9-39)
- OTHER hypocaloric diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 4 |
What the finished NCT03101930 record still lists
NCT03101930 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 5 interventions - of which Sitagliptin is the first listed.
NCT03101930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03101930 about?
NCT03101930 is a clinical study titled "Cardiovascular Effects of GLP-1 Receptor Activation". This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual ...
What is the current status of trial NCT03101930?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 329 participants. The study started on 2017-05-01. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03101930?
The interventions under investigation include: Sitagliptin (DRUG), Placebos (DRUG), Liraglutide (DRUG), Exendin (9-39) (DRUG), hypocaloric diet (OTHER).
Who is sponsoring clinical trial NCT03101930?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03101930's enrollment target sits among peer trials
329 253rd of 2000 higher than 1,748 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI